BURLINGTON, VT - Federal health inspectors found that Elderwood at Burlington failed to prevent the unnecessary use of psychotropic medications on residents, according to a complaint investigation completed on August 11, 2025. The finding raises important questions about chemical restraint practices in long-term care facilities across Vermont.
Federal Investigation Reveals Psychotropic Medication Concerns
The complaint investigation at Elderwood at Burlington, located in Burlington, Vermont, resulted in two deficiencies being cited against the facility. The most notable citation fell under regulatory tag F0605, which addresses the requirement that nursing homes prevent the use of unnecessary psychotropic medications or medications that may restrain a resident's ability to function.
The citation falls under the broader category of Freedom from Abuse, Neglect, and Exploitation, one of the most closely monitored areas in federal nursing home oversight. The deficiency was classified at Scope/Severity Level D, meaning inspectors identified an isolated incident where no actual harm was documented, but the potential existed for more than minimal harm to residents.
While the severity level indicates no resident was directly harmed, the classification acknowledges a meaningful risk. Psychotropic medications — a broad class of drugs that includes antipsychotics, anti-anxiety medications, sedatives, and antidepressants — carry well-documented risks for elderly residents in long-term care settings, making even a single instance of unnecessary use a matter of regulatory concern.
The facility reported it had corrected the deficiency as of September 8, 2025, approximately four weeks after the inspection date.
Understanding Psychotropic Medications in Nursing Homes
Psychotropic medications alter brain chemistry to affect mood, perception, consciousness, and behavior. In nursing home settings, these drugs serve legitimate clinical purposes when properly prescribed for diagnosed psychiatric conditions such as major depression, schizophrenia, bipolar disorder, or severe anxiety disorders.
However, the use of these powerful medications becomes problematic — and potentially constitutes a form of chemical restraint — when they are administered primarily for the convenience of staff rather than for a documented medical condition. A chemical restraint is any drug used to manage a resident's behavior, restrict movement, or impair function when it is not a standard treatment for the resident's diagnosed condition.
Federal regulations under 42 CFR §483.45 are specific on this point: each resident's drug regimen must be free from unnecessary drugs. A drug is considered unnecessary when it is used in excessive doses, for an excessive duration, without adequate monitoring, without adequate indications for its use, or in the presence of adverse consequences that indicate the dose should be reduced or discontinued.
Antipsychotic medications, in particular, have been a focal point of federal regulatory efforts for more than a decade. The Centers for Medicare & Medicaid Services (CMS) launched the National Partnership to Improve Dementia Care in Nursing Homes in 2012, specifically targeting the overuse of antipsychotic drugs among residents with dementia. These medications carry an FDA black-box warning — the agency's most serious safety alert — indicating that antipsychotics increase the risk of death in elderly patients with dementia-related psychosis.
Medical Risks of Unnecessary Psychotropic Use in Elderly Residents
The physiological risks associated with unnecessary psychotropic medication in elderly nursing home residents are substantial. Aging bodies metabolize drugs differently than younger individuals, leading to increased sensitivity and prolonged drug effects. Several key risk factors are directly relevant to long-term care populations.
Falls and fractures represent one of the most immediate dangers. Psychotropic medications frequently cause dizziness, sedation, and impaired balance. For elderly residents who may already have compromised mobility, osteoporosis, or muscle weakness, the addition of a sedating medication significantly elevates the risk of a fall. Hip fractures resulting from falls in elderly populations carry a one-year mortality rate of approximately 20-30%, making fall prevention a critical safety priority.
Cognitive decline is another documented consequence. Sedating medications can accelerate confusion and disorientation in elderly patients, particularly those with existing cognitive impairment. Residents may become less able to communicate their needs, participate in their own care, or engage in social activities — all of which are protected rights under federal nursing home regulations.
Cardiovascular complications are also associated with many psychotropic drugs. Certain antipsychotic medications can cause changes in heart rhythm, low blood pressure upon standing (orthostatic hypotension), and increased risk of stroke. These cardiovascular effects pose particular danger to elderly residents who frequently have pre-existing heart conditions.
Metabolic effects including weight gain, elevated blood sugar, and changes in cholesterol levels are well-documented side effects of several classes of psychotropic medications. For residents already managing diabetes or cardiovascular disease, these metabolic changes can complicate existing treatment plans and worsen health outcomes.
Additionally, prolonged unnecessary use of psychotropic medications can result in physical dependence, making it difficult to discontinue the medication without withdrawal symptoms. This creates a cycle where a drug that was never medically necessary becomes a drug that is difficult to safely stop.
Impact on Resident Function and Quality of Life
Beyond the direct medical risks, unnecessary psychotropic medication use can profoundly affect a resident's daily functioning and quality of life. Residents who are overmedicated may experience excessive drowsiness, making them unable to participate in meals, therapy sessions, social activities, or family visits. This level of sedation effectively removes a resident from meaningful daily life.
Federal regulations explicitly protect residents' rights to be free from chemical restraints, to participate in their own care planning, and to engage in activities of their choosing. When medications impair a resident's ability to exercise these rights, the facility may be in violation of multiple regulatory standards simultaneously.
Regulatory Framework and Industry Standards
The citation against Elderwood at Burlington invokes F-tag F0605, which corresponds to the federal requirement under §483.45(e) of the Code of Federal Regulations. This regulation requires nursing facilities to ensure that residents are free from unnecessary medications, with specific attention to psychotropic drugs.
Under current CMS guidelines, facilities must meet several requirements before administering psychotropic medications:
- A documented diagnosis that supports the use of the specific medication - Evidence that non-pharmacological interventions were attempted before resorting to medication - A gradual dose reduction plan unless clinically contraindicated - Ongoing monitoring for side effects and therapeutic effectiveness - Informed consent from the resident or their legal representative - Regular review of the medication's continued necessity by the prescribing physician and the facility's consultant pharmacist
Industry best practices emphasize a person-centered approach to behavioral management. Before considering psychotropic medication, facilities are expected to investigate underlying causes of behavioral changes — which may include pain, infection, environmental factors, unmet needs, or medication side effects from other drugs. Non-pharmacological interventions such as structured activities, environmental modifications, consistent staffing, and individualized care plans are considered the appropriate first-line response.
Correction Timeline and Facility Response
Following the August 11, 2025 inspection, Elderwood at Burlington was given a deadline for correction. The facility reported that the identified deficiency was corrected as of September 8, 2025, a timeline of approximately four weeks from the date of the citation.
The correction status is listed as "Deficient, Provider has date of correction," indicating that the facility acknowledged the deficiency and took steps to address it within the required timeframe. The specific corrective actions taken by the facility — which may include revised medication review protocols, additional staff training, updated care plans, or enhanced monitoring procedures — would be detailed in the facility's plan of correction submitted to the state survey agency.
It is worth noting that this citation was one of two deficiencies identified during the complaint investigation. The fact that the inspection was prompted by a complaint, rather than being a routine survey, indicates that a concern was raised by a resident, family member, staff member, or other party — and that state and federal investigators determined the complaint warranted an on-site investigation.
Broader Context: Psychotropic Medication Use in U.S. Nursing Homes
The citation at Elderwood at Burlington reflects an ongoing national challenge. Despite more than a decade of focused regulatory and public awareness efforts, the use of psychotropic medications in nursing homes — particularly antipsychotics — remains a significant concern across the United States.
CMS publicly reports antipsychotic medication usage rates for every Medicare-certified nursing home in the country through its Nursing Home Compare database (now part of the Care Compare system). These rates allow families, advocates, and regulators to compare individual facility practices against state and national averages.
Nationally, the rate of antipsychotic medication use among long-stay nursing home residents has decreased from approximately 24% at the start of the National Partnership initiative in 2012 to lower levels in subsequent years, though progress has been uneven across states and individual facilities. Experts in geriatric pharmacology note that the appropriate rate is not zero — some residents have legitimate psychiatric diagnoses requiring these medications — but unnecessary use remains a persistent problem.
Vermont's Department of Disabilities, Aging and Independent Living oversees nursing home inspections in coordination with CMS. Families of residents at any Vermont nursing facility can access inspection reports, including the full details of citations like the one at Elderwood at Burlington, through the CMS Care Compare website or by contacting the state survey agency directly.
What Families Should Know
For families with loved ones in nursing home care, psychotropic medication use is an area that warrants close attention. Key steps include:
- Reviewing the medication list regularly and asking the care team to explain the purpose, expected benefits, and potential side effects of every drug - Asking whether non-pharmacological approaches were tried before any psychotropic medication was prescribed - Requesting information about gradual dose reduction plans for any antipsychotic medication - Monitoring for signs of overmedication, such as excessive drowsiness, sudden changes in alertness, new difficulty walking, or withdrawal from social activities - Checking facility inspection reports on the CMS Care Compare website for any citations related to medication management
The full inspection report for Elderwood at Burlington, including details on both deficiencies cited during the August 2025 complaint investigation, is available through federal and state regulatory databases.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Elderwood At Burlington from 2025-08-11 including all violations, facility responses, and corrective action plans.
💬 Join the Discussion
Comments are moderated. Please keep discussions respectful and relevant to nursing home care quality.